Patent · US Active

Trimethylangelicin as CFTR corrector in bronchial epithelial cells

US9283206B2 · kind B2 · utility

0Cited by

1References

2Claims

0Family size

Assignees

Azienda Ospedaliera Universitaria Integrata di Verona · IT
UNIVERSITA' DEGLI STUDI DI FERRARA · IT
UNIVERSITA' DEGLI STUDI DI · IT
RARE PARTNERS SRL · IT

Inventors

Giulio Cabrini · Verona, IT
Valeria Casavola · Bari, IT
Roberto Gambari · Bologna, IT

Key dates

Filing date	Jun 13, 2012
Grant date	Mar 15, 2016
Priority date	—
Expiry date	Nov 18, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of 4,6,4′-trimethylangelicin (TMA) and structural analogs thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.